US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

SpyGlass Pharma Inc (SGP): Med-Tech Vision Pays Off: SpyGlass Pharma IPO Pops on Day One

SpyGlass Pharma Inc (SGP): IPO Draws Demand as Med-Tech Story Gains Traction

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>SpyGlass Pharma surged 65% on its first day, reflecting strong demand for its novel glaucoma and cataract treatment platform.</li>
<li>Shares declined from the IPO high but maintained a premium to the $16.00 offering price throughout the first 180 days.</li>
<li>Future upside will likely require positive clinical progress, with potential financing opportunities if investor momentum returns.</li>
</ul>


SpyGlass Pharma surged 65% on its first day, reflecting strong demand for its novel glaucoma and cataract treatment platform.
Shares declined from the IPO high but maintained a premium to the $16.00 offering price throughout the first 180 days.
Future upside will likely require positive clinical progress, with potential financing opportunities if investor momentum returns.


SpyGlass Pharma (SGP): Six Months Later: Strong Debut Holds Above Water as Investors Await Data